Consistent with the inhibition of the PD-L1 pathway by CX-072, we found an increase in CD8+ T cells and elevation of cytotoxic T-cell markers in the tumor of the one CX-072 monotherapy patient whose biopsy met evaluability criteria. The gene discussed is CD274; the disease is neoplasm.